STRATA Skin Sciences’ TheraClear®X Acne Therapy System Found Safe and Effective in Study Published in Peer Reviewed Journal
Study published in
In the study, the TheraClear®X Acne Therapy System was shown to reduce lesions and associated skin redness with improvement in skin texture and pore size after one to three treatments with infrequent adverse effects, providing benefit as monotherapy and/or as an adjuvant. The ability to change pulse structure, pulse duration, vacuum pressure, and fluence (i.e., energy intensity) allowed for treatment that best matched skin type and acne therapy.
The study sought to evaluate visible improvements in acne lesions and skin texture after a series of tailored photopneumatic therapy applications delivered to patients with mild-moderate acne. Seven female patients with inflammatory, comedonal, and pustular lesions were evaluated after up to six treatments, one to two weeks apart for 15-20 minutes per treatment using customized energy settings. The results demonstrate:
- All patients experienced a visible reduction in comedones, pustules, and inflammatory acne lesions and achieved ≥ 50% clearance after three treatments
- Patients also experienced overall improvements in skin texture with reduction in redness, pore size, oiliness, perilesional erythema, and acne-induced hyperpigmentation
- Side effects experienced by patients were mild and transient and included mild erythema, mild bruising, superficial erosions, and temporary pigmentation changes (48–72 hours post-treatment)
- All patients stated that TheraClear®X treatment was "comfortable"
The study was conducted by
“I am very satisfied with the study results. The study shows TheraClear®X as a monotherapy is well tolerated and delivers visible improvements in facial acne lesions and skin texture,” commented
STRATA’s TheraClearX is a photopneumatic device that is FDA-cleared as a noninvasive, in-office treatment for mild-to-moderate acne, including comedonal, pustular, and inflammatory acne vulgaris. TheraClearX combines gentle vacuum with pulsed broadband light to treat acne. The vacuum pulls dermal structures toward the skin surface and withdraws the contents of the follicles. Broadband light activates porphyrins to destroy Cutibacterium acnes and reduce sebum production. The vacuum is released when the process is completed. The treatment is administered through a handheld delivery system that is liquid-cooled for patient comfort and has no patient downtime. Treatment requires no pre-medication or anesthesia.
“The results of this study are consistent with known clinical use of the TheraClear®X device and other published studies that demonstrate the benefits of photopneumatic therapy in the treatment of mild to moderate acne,” said STRATA’s President and CEO Dr.
The full study can be accessed with the following link:
https://doi.org/10.1080/14764172.2024.2376704
About
STRATA is proud to offer these exciting technologies in the
Safe Harbor
This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to launch and sell products recently acquired or to be developed in the future, the Company’s ability to develop social media marketing campaigns, direct to consumer marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions labor supply shortages, or supply chain interruptions resulting from fiscal, political factors, international conflicts, responses, or conditions affecting the Company, the medical device industry and our customers and patients in general, as well as more specific risks and uncertainties set forth in the Company’s
Investor Contact:
CORE IR
516-222-2560
IR@strataskin.com
Source: STRATA Skin Sciences, Inc.